Nissim Mashiach
LPTXAbout Nissim Mashiach
Nissim Mashiach, age 64, has served as an independent director of Leap Therapeutics (LPTX) since January 2017. He is a co‑founder of Nubiyota LLC and previously served as President & CEO of Macrocure Ltd. until its merger with Leap in 2017. He holds an MBA (University of Manchester), an MPharmSc (Hebrew University), and a BSc in Chemical Engineering (Technion). He is currently a director and audit committee member at MediWound Ltd. (Nasdaq: MDWD) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Macrocure Ltd. | President & Chief Executive Officer | Jun 2012 – Jan 2017 | Led company through merger with Leap Therapeutics |
| Ethicon (J&J) | General Manager | Jan 2009 – Jan 2012 | Senior operating leadership at J&J subsidiary |
| Omrix Biopharmaceuticals (acquired by J&J in 2008) | President & Chief Operating Officer | Pre‑2008 | Executive operating leadership prior to acquisition by J&J |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| MediWound Ltd. (Nasdaq: MDWD) | Director; Audit Committee Member | Since Jun 2017 | Audit committee service; independent director |
| Nubiyota LLC | Co‑founder | Current | Microbiome‑focused, clinical stage company |
Board Governance
| Item | Detail |
|---|---|
| Board class/term | Class III director; term expires at 2026 annual meeting |
| Independence | Board determined independent under Nasdaq rules; audit committee independence satisfied |
| Committee assignments | Audit Committee Member (not chair) |
| Committee activity | Audit Committee met 5 times in 2024 |
| Board activity & attendance | Board met 5 times in 2024; each director attended at least 75% of Board and applicable committee meetings |
| Lead Independent Director (board structure context) | Thomas Dietz serves as Lead Independent Director |
Fixed Compensation (Director)
| Component (FY2024) | Amount (USD) |
|---|---|
| Annual cash retainer | $45,000 |
| Audit Committee member fee | $10,000 |
| Other reimbursed expenses | $429 |
| Total cash/other | $55,429 |
Notes:
- 2025 fee schedule (for context): Audit Committee member $10,000; base non‑employee director $45,000; additional leadership retainers apply by role .
Performance Compensation (Director Equity)
| Item | Detail |
|---|---|
| Option awards grant-date fair value (FY2024) | $98,055 |
| Equity instruments | Time‑vested stock options; typical grants of 25,000 options in Jan 2024 and 25,000 in Oct 2024 to non‑lead independent directors; vest quarterly over 1 year; exercise price at grant FMV |
| Performance metrics | Director equity is service‑based (no disclosed performance metrics for director awards) |
Other Directorships & Interlocks
| Company | Role | Potential Interlock/Notes |
|---|---|---|
| MediWound Ltd. (Nasdaq: MDWD) | Director; Audit Committee Member | External public board; no related‑party transaction with Leap disclosed |
Expertise & Qualifications
- Operating executive leadership (CEO/COO/GM roles across biopharma and J&J subsidiaries) .
- Audit committee experience (MediWound; LPTX audit committee member) .
- Education: MBA (University of Manchester); MPharmSc (Hebrew University); BSc Chemical Engineering (Technion) .
Equity Ownership
| Measure | Value |
|---|---|
| Beneficial ownership (as of Apr 21, 2025) | 93,355 shares; <1% of outstanding |
| Director option holdings (Dec 31, 2024) | 92,928 options exercisable; 25,000 unexercisable; total 117,928 |
| Pledging/hedging | Company policy prohibits hedging and pledging by directors, officers, employees |
Governance Assessment
- Strengths: Independent status; audit committee membership; audit committee service at another public company; solid operating background; compliant attendance (≥75%); equity grants help align interests .
- Compensation alignment: Mix is modest cash retainers plus time‑vested options (no performance equity for directors), consistent with small‑cap biotech governance norms .
- Conflicts/related‑party exposure: No related‑party transactions disclosed involving Mr. Mashiach; Leap maintains a related‑party transaction approval policy overseen by the Nominating & Corporate Governance Committee .
- Board‑level watch items (context): Ongoing Nasdaq minimum bid price remediation with potential reverse stock split authority; significant 2025 financing with investor‑designee board nomination rights (Winklevoss) could alter board dynamics—no direct link to Mr. Mashiach but relevant to overall board effectiveness and independence oversight .
Notes on Policies and Practices
- Insider trading/hedging: Hedging and pledging of company securities prohibited; no margin accounts permitted for directors/officers/employees .
- Committee independence and charters: Committee compositions and charters comply with Nasdaq/SEC requirements; audit committee chaired by Thomas Dietz; audit committee met 5 times in 2024 .
Appendix: Director Compensation (FY2024) – Detail
| Component | Amount (USD) |
|---|---|
| Fees Earned (cash) | $55,000 |
| Option Awards (grant-date fair value) | $98,055 |
| Other Compensation (expense reimbursement) | $429 |
| Total | $153,484 |
All citations:
- Biography, external roles, education: .
- Board class/term, board composition: .
- Independence determinations: .
- Committees and activity: .
- Board meetings and attendance threshold: .
- Director fee schedule and compensation: .
- Director option holdings: .
- Beneficial ownership: .
- Related‑party transactions policy and disclosures: .
- Insider trading/hedging/pledging policy: .
- Nasdaq compliance and reverse split authority context: .
- Investor‑designee nomination rights (Lead Investor Agreement): .